Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure In India To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis has had an interesting past in India from having a discovery research center to creating some of the most recognized pharmaceutical brands. But its Managing Director Shailesh Ayyangar is not resting on those achievements. The senior executive who started with Ranbaxy and also worked at SmithKline Beecham in key positions is now taking up the daunting challenge of creating a new paradigm in the rural centers of India. An exercise that requires huge investments, navigation of unseen opposition along with perseverance to witness a real change excites Ayyangar. In a rare interview, Ayyangar spoke to PharmAsia News' India Bureau about the company's rural markets strategy, creating brands, doing research deals and also about buying out "strategically important" companies.
You may also be interested in...
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules